9 of 10 HAE patients attack free with NTLA-2002, gene-editing therapy
Over the months after a single treatment with the experimental gene-editing therapy NTLA-2002, nine of 10 people with hereditary angioedema (HAE) in a Phase 1/2 trial have been free from swelling attacks. Three patients with high pretreatment attack rates, ranging from 4.4 to 16.8 each month, have gone without…